Lupin launches generic KCl for Oral Solution USP, 20 mEq
20 November 2019 | News
It is indicated for the treatment and prophylaxis of hypokalemia
Lupin has announced the launch of Potassium Chloride (KCl) for Oral Solution USP, 20 mEq, having received an approval from the USFDA earlier.
Lupin’s Potassium Chloride for Oral Solution USP, 20 mEq, is the generic equivalent of Pharma Research Software Solution, LLC’s Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of approximately USD 90 million in the U.S. (IQVIA MAT September 2019).
